| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,900 | 8,550 | 06.06. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Bavarian Nordic A/S: Bavarian Nordic Launches Next Tranche of Share Buy-Back Program | 10 | GlobeNewswire (USA) | ||
| 13.05. | Bavarian Nordic A/S: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such | 25 | GlobeNewswire (USA) | ||
| 13.05. | Bavarian Nordic A/S Reveals Decline In Q1 Income | 25 | RTTNews | ||
| BAVARIAN NORDIC A/S ADR Aktie jetzt für 0€ handeln | |||||
| 13.05. | Bavarian Nordic A/S: Bavarian Nordic Announces Interim Results for the First Three Months of 2026 | 468 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, May 13, 2026 - Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026.
Revenue for the first... ► Artikel lesen | |
| 12.05. | Bavarian Nordic Raises 2026 Guidance After Additional U.S. Vaccine Order | 14 | RTTNews | ||
| 11.05. | Bavarian Nordic A/S: Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines | 1.047 | GlobeNewswire (Europe) | Exercised options total USD 97 million, covering manufacturing of bulk vaccine and supply of freeze-dried vaccines.Company upgrades full-year financial guidance
COPENHAGEN, Denmark, May 11, 2026... ► Artikel lesen | |
| 11.05. | Bavarian Nordic A/S: Bavarian Nordic - Completion of Share Buy-Back Program | 18 | GlobeNewswire (USA) | ||
| 04.05. | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | 7 | GlobeNewswire (USA) | ||
| 27.04. | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | 5 | GlobeNewswire (USA) | ||
| 21.04. | Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S | 351 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, April 21, 2026 - Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2025 was adopted. The Board of Directors'... ► Artikel lesen | |
| 20.04. | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | 7 | GlobeNewswire (USA) | ||
| 16.04. | Bavarian Nordic A/S: Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine | 639 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, April 16, 2026 - Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA (recombinant, adsorbed) for active... ► Artikel lesen | |
| 13.04. | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | 4 | GlobeNewswire (USA) | ||
| 07.04. | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | 9 | GlobeNewswire (USA) | ||
| 30.03. | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | 10 | GlobeNewswire (USA) | ||
| 27.03. | Bavarian Nordic A/S: Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years | 683 | GlobeNewswire (Europe) | Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults.
COPENHAGEN... ► Artikel lesen | |
| 24.03. | Bavarian Nordic A/S - Notice Convening Annual General Meeting | 6 | GlobeNewswire (USA) | ||
| 23.03. | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | 9 | GlobeNewswire (USA) | ||
| 16.03. | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | 4 | GlobeNewswire (USA) | ||
| 12.03. | Bavarian Nordic A/S: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such | 9 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,05 | -1,34 % | BioNTech und BMS melden neue Daten für Lungenkrebskandidat Pumitamig | BioNTech SE und Bristol Myers Squibb haben auf dem ASCO-Jahreskongress in Chicago erste globale Phase-2-Daten für den bispezifischen Immunmodulator Pumitamig in Kombination mit Chemotherapie bei fortgeschrittenem... ► Artikel lesen | |
| EVOTEC | 4,932 | -3,58 % | EQS-News: Evotec SE: Evotec ernennt Rui Wang zum Head of Global In Silico & AI | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Rui Wang zum Head of Global In Silico & AI
02.06.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| MODERNA | 41,190 | +0,12 % | Neue CAR-T-Erfolge bei Autoimmunerkrankungen: Warum Lösungen für Zelltherapien vor dem nächsten Wachstumsschub stehen könnten | ||
| PAION | 0,062 | -23,60 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,331 | -0,64 % | Valneva im Höhenflug: Das Signal das die meisten Anleger noch nicht kennen - Meine Einschätzung für die neue Börsenwoche | ||
| AMGEN | 306,30 | +0,97 % | EQS-News: Amgen: Europäische Kommission erteilt Zulassung für Imdylltra von Amgen für die Behandlung von kleinzelligem Lungenkrebs im fortgeschrittenen Stadium | EQS-News: Amgen
/ Schlagwort(e): Sonstiges/Sonstiges
EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| NOVAVAX | 8,080 | -1,70 % | NOVAVAX INC: Stabilität vor der nächsten Bewegung | ||
| STRYKER | 265,60 | +0,15 % | Leerink cuts Stryker stock price target to $407 on model update | ||
| BIOGEN | 171,56 | +1,19 % | Biogen's Salanersen Wins FDA Breakthrough Therapy Designation For Spinal Muscular Atrophy Treatment | WESTON (dpa-AFX) - Thursday, Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular... ► Artikel lesen | |
| ILLUMINA | 139,80 | -0,70 % | ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge? | ||
| CRISPR THERAPEUTICS | 44,705 | -0,60 % | CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline | ||
| NANOREPRO | 1,855 | +2,77 % | EQS-DD: NanoRepro AG: Lisa Jüngst, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
01.06.2026 / 09:43... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,200 | +3,65 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 551,40 | +0,04 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen |